Pharma

Your Article Summary

See Latest Articles

Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
Amgen, 06/23/09

Amgen Inc. announced that the U.S. Food and Drug Administration has asked the company to participate in a meeting of the Reproductive Health Drugs Advisory Committee on Aug. 2009. The RHDAC will review data supporting the Biologics License Application for denosumab, a RANK Ligand inhibitor for which Amgen is seeking approval for prevention and treatment of postmenopausal osteoporosis and prevention and treatment of bone loss in patients undergoing hormone ablation for either prostate or breast cancer.

Today in Conferences/Meetings...keeping you current

Receive free subspecialty "5-minute updates" via email

ImmunoGen, Inc. Announces Clinical Data Presentations on Three TAP Compounds at Upcoming ASH Annual Meeting and Exposition
ImmunoGen, Inc., 11/25/09

AMA meeting: Nap time mandate for on-call residents rejected
American Medical News , 11/25/09

AMA meeting: Delegate vote refines AMA stance on system reform
American Medical News , 11/25/09

 See all of Conferences/Meetings